With the global pharmaceutical industry expected to be worth
£800bn by 2020, the pressure is on to improve efficiency and
decision-making in drug research. New drug pipelines are
dwindling and the cost of failure is high. The estimated cost of
taking a single drug to market is $350 million, and with regulatory
agencies demanding more, larger and longer studies due to the
increased desire for niche therapies, this figure is only going to
increase further. Elliott Frodsham, Business Development and
Operations Assistant at Datatrial, shares his thoughts on datadriven
drug pricing.
https://international-pharma.com/wp-content/uploads/2016/07/Tech-2-Data-driven-Drug.pdf